Garheng Kong's most recent trade in Xeris Biopharma Holdings Inc was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 50,000 | 214,144 (0%) | 0% | 0 | Common Stock | |
| Labcorp | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 897 | 897 | - | - | Restricted Stock Unit | |
| Labcorp | Garheng Kong | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 944 | 12,842 (0%) | 0% | - | Common Stock | |
| Labcorp | Garheng Kong | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 944 | 0 | - | - | Restricted Stock Unit | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 50,000 | 164,144 (0%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Other type of transaction at price $ 0.00 per share. | 15 Mar 2024 | 6,474 | 114,144 (0%) | 0% | - | Common Stock | |
| Labcorp | Garheng Kong | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 11,898 (0%) | 0% | - | Common Stock | |
| Labcorp | Kong Garheng | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 944 | - | - | Restricted Stock Unit | |
| Labcorp | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 944 | 1,891 | - | - | Restricted Stock Unit | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 42,500 | 107,670 (0%) | 0% | 0 | Common Stock | |
| Venus Concept Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 75,000 | 75,000 | - | - | Employee Stock Option (Right to Buy) | |
| Labcorp | Garheng Kong | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 849 | - | - | Restricted Stock Unit | |
| Labcorp | Garheng Kong | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 10,951 (0%) | 0% | - | Common Stock | |
| Labcorp | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 849 | 1,591 | - | - | Restricted Stock Unit | |
| Alimera Sciences Inc. | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Venus Concept Inc | Garheng Kong | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 18 Nov 2022 | 335,000 | 335,000 | - | - | Voting Convertible Preferred Stock | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 15,000 | 65,170 (0%) | 0% | 0 | Common Stock | |
| Venus Concept Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2022 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Labcorp | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 742 | 742 | - | - | Restricted Stock Unit | |
| Labcorp | Garheng Kong | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2022 | 771 | 0 | - | - | Restricted Stock Unit | |
| Labcorp | Garheng Kong | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2022 | 771 | 10,209 (0%) | 0% | - | Common Stock | |
| Venus Concept Inc | Garheng Kong | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.25 per share. | 15 Dec 2021 | 1,600,000 | 6,795,621 (22%) | 5% | 1.3 | 2,000,000 | Common Shares |
| Alimera Sciences Inc. | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2021 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 50,170 | 50,170 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 31,360 | 31,360 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 31,360 | 31,360 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 31,360 | 31,360 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 19,650 | 19,650 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 19,600 | 19,600 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 7,357 | 7,357 | - | - | Stock Option (Right to Buy) | |
| Venus Concept Inc | Garheng Kong | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 25,000 | 25,000 | - | - | Director Stock Option (Right to Buy) | |
| Labcorp | Garheng Kong | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 986 | 771 | - | - | Restricted Stock Unit | |
| Labcorp | Garheng Kong | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 986 | 9,438 (0%) | 0% | - | Common Stock | |
| Labcorp | Garheng Kong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 771 | 1,757 | - | - | Restricted Stock Unit |